8-K: Modular Medical Gets Nasdaq Extension to Avoid Delisting

Modular Medical, Inc. has received a 180-day extension from Nasdaq to regain compliance with the minimum $1 bid price requirement, pushing the deadline to June 29, 2026.

Summary

• Modular Medical, Inc. (MODD) received a 180-day extension from Nasdaq to regain compliance with the minimum $1 bid price rule.
• The new deadline for compliance is June 29, 2026.
• To regain compliance, the common stock's bid price must close at $1.00 or more for a minimum of 10 consecutive business days.
• Failure to comply by the deadline could lead to delisting, with the possibility of an appeal to a Nasdaq hearings panel, though success is not assured.
• The extension has no immediate impact on the listing or trading of MODD common stock on the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: The company received an extension to address its Nasdaq listing compliance issue, which temporarily alleviates the immediate threat of delisting but highlights ongoing share price weakness. The underlying business context (insulin delivery tech) is positive, but the immediate news is about a regulatory challenge.

Positives

• Received a 180-day extension, providing more time to meet Nasdaq's minimum bid price requirement.
• No immediate effect on the listing or trading of the common stock.
• The company has an FDA-cleared patch pump designed for "almost-pumpers," indicating a product in the market or near market.
• The company's founder, Paul DiPerna, has a strong track record, having founded Tandem Diabetes and invented the t:slim insulin pump.

Negatives

• The company's common stock bid price has been below the minimum $1 requirement for 30 consecutive business days, indicating significant share price weakness.
• Risk of delisting from Nasdaq if compliance is not regained by June 29, 2026.
• No assurance that an appeal to a Nasdaq hearings panel would be successful if delisting occurs.

Risks

• Failure to meet the minimum bid price requirement during the extended compliance period or in the future.
• Failure to meet other requirements for continued listing under Nasdaq Listing Rules.
• Nasdaq may not grant further relief from delisting if necessary.
• The company may not ultimately meet applicable Nasdaq requirements even if any such relief is necessary.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with the Nasdaq Bid Price Rule. It also plans to appeal any future delisting determination if necessary, though success is not guaranteed.

Management Comments

• The Company will continue to monitor the closing bid price of the Common Stock and evaluate its available options to regain compliance with the Bid Price Rule.
• The Company does not assume any obligation to update any forward-looking statements.

Industry Context

Modular Medical operates in the medical device industry, specifically focusing on insulin delivery technology. Its FDA-cleared patch pump aims to serve the 'almost-pumpers' segment, suggesting a strategy to broaden market access beyond traditional 'superusers' by offering an affordable and user-friendly design. This positions the company to potentially compete with existing insulin pump manufacturers by targeting a different user demographic with a focus on simplicity and cost-effectiveness.

Stakeholder Impact

• Shareholders: Face uncertainty regarding the company's continued listing on Nasdaq and potential delisting if compliance is not regained. The extension provides temporary relief but does not resolve the underlying share price issue.
• Employees: No direct impact mentioned, but delisting could affect company morale and future prospects.
• Customers: No direct impact mentioned on product availability or service.
• Creditors/Suppliers: No direct impact mentioned, but delisting could affect the company's ability to raise capital or its perceived financial stability.

Next Steps

• Monitor the closing bid price of the common stock.
• Evaluate available options to regain compliance with the Bid Price Rule.
• If non-compliant by June 29, 2026, the company may appeal a delisting determination to a Nasdaq hearings panel.

Key Dates

Recommendation

The company has received a critical extension from Nasdaq, temporarily mitigating the immediate threat of delisting. While this provides a window for the company to address its share price, the underlying issue of non-compliance with the minimum bid price rule persists. Investors should hold to observe if the company can successfully regain compliance and demonstrate fundamental improvements that would support a higher share price, rather than making a decision based solely on this temporary regulatory reprieve.

Keywords

Modular Medical, MODD, Nasdaq, delisting, minimum bid price, insulin pump, medical device, diabetes technology, stock market compliance